We read with great interest the article by JF Martín-Sánchez [
[1]
] commenting on our article "Comorbidities in chronic heart failure: An update from
Italian Society of Cardiology (SIC) Working Group on Heart Failure" [
[2]
]. In his editorial, FJ Martín-Sánchez highlights the need to consider two others specific
issues related to comorbidity in heart failure (HF), such as polypharmacy and frailty,
to improve outcomes in HF patients with comorbidity. We strongly agree on what is
reported about these two issues. In particular, we join the recommendation to minimize
the polypharmacy, particularly in case of advanced renal and/or hepatic failure [
- Correale M.
- Paolillo S.
- Mercurio V.
- Limongelli G.
- Barillà F.
- Ruocco G.
- Palazzuoli A.
- Scrutinio D.
- Lagioia R.
- Lombardi C.
- Lupi L.
- Magrì D.
- Masarone D.
- Pacileo G.
- Scicchitano P.
- Matteo Ciccone M.
- Parati G.
- Tocchetti C.G.
- Nodari S.
Comorbidities in chronic heart failure: an update from Italian society of cardiology
(SIC) working group on heart failure.
Eur J Intern Med. 2020; 71: 23-31
[3]
,
[4]
] and in case of poor hemodynamic condition and, finally, in the palliative care [
- Correale M.
- Tricarico L.
- Leopizzi A.
- Mallardi A.
- Mazzeo P.
- Tucci S.
- Grazioli D.
- Di Biase M.
- Brunetti N.D.
Liver disease and heart failure: an uptodate.
Panminerva Med. 2019; https://doi.org/10.23736/S0031-0808.19.03768-6
[5]
]. This is a very important topic, above all, for elderly patients, who take multiple
medications and frequently have renal failure. FJ Martín-Sánchez also cites several
possible interventions to decrease the risk of adverse drug events. These interventions
should be implemented in the clinical practice.- Antonione R.
- Sinagra G.
- Moroni M.
- Correale M.
- Redaelli D.
- Scrutinio D.
- Malinverni E.
- Nodari S.
- Calabrò R.
- Penco I.
- Mercuro G.
[Palliative care in the cardiac setting: a consensus document of the Italian society
of cardiology/Italian society of palliative care (SIC/SICP)].
G Ital Cardiol (Rome). 2019; 20: 46-61
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Comprehensive heart failure assessment: a challenge to modify the course of heart failure.Eur J Intern Med. 2020; 71: 8-10
- Comorbidities in chronic heart failure: an update from Italian society of cardiology (SIC) working group on heart failure.Eur J Intern Med. 2020; 71: 23-31
- Liver disease and heart failure: back and forth.Eur J Intern Med. 2018; 48: 25-34
- Liver disease and heart failure: an uptodate.Panminerva Med. 2019; https://doi.org/10.23736/S0031-0808.19.03768-6
- [Palliative care in the cardiac setting: a consensus document of the Italian society of cardiology/Italian society of palliative care (SIC/SICP)].G Ital Cardiol (Rome). 2019; 20: 46-61
- “Insufficienza del cuore destro e sinistro group, a research group of the Italian society of cardiology. management of heart failure in the new era: the role of scores.J Cardiovasc Med (Hagerstown). 2016; 17: 569-580
- Dapagliflozin in patients with heart failure and reduced ejection fraction.N Engl J Med. 2019; 381: 1995-2008
- 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.Eur Heart J. 2020; 41 (Jan 7): 255-323https://doi.org/10.1093/eurheartj/ehz486
- Redefining biomarkers in heart failure.Heart Fail Rev. 2018; 23: 237-253https://doi.org/10.1007/s10741-018-9683-2
Article info
Publication history
Published online: February 08, 2020
Accepted:
January 29,
2020
Received:
January 14,
2020
Identification
Copyright
© 2020 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Comorbidities in chronic heart failure: An update from Italian Society of Cardiology (SIC) Working Group on Heart FailureEuropean Journal of Internal MedicineVol. 71
- PreviewThe Prevalence of Heart Failure (HF) in the western world is around 1-2% and more than 10% over 70 years of age and the incidence is about 5–10 per 1000 persons per year, representing the leading cause of outpatient visits and the most frequent reason of hospitalization for patients over 65 years of age [1]. Comorbidities are a major issue in HF, leading to poor outcomes, excessive hospitalization and mortality. Comorbidities may be subdivided into cardiovascular (CV) and non-CV. HF in elderly patients is associated with more widespread symptoms and signs due to the presence of non-CV comorbidities.
- Full-Text
- Preview
- Comprehensive heart failure assessment: A challenge to modify the course of heart failureEuropean Journal of Internal MedicineVol. 71
